💊FDA Approval Update | #FDA recently approved #Yartemlea (#Narosoplimab-wuug) for #hematopoietic stem cell #transplant (#HSCT)-associated thrombotic microangiopathy
🔸Inhibits #lectin pathway effector enzyme — #MASP2
#HematopoieticStemCell #ThromboticMicroangiopathy

Pleased to announce FDA approval of YARTEMLEA® (narsoplimab-wuug). First and only approved lectin pathway inhibitor therapy indicated for TA-TMA.
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA